O&M and asset management have evolved from basic maintenance in the early days of solar technology to a highly sophisticated, ...

Thermo Fisher is facing macro headwinds, but execution remains solid. Click here to read why I’m maintaining my Buy rating ...

Many Boston Scientific Corporation insiders ditched their stock over the past year, which may be of interest to the company's shareholders. When analyzing insider transactions, it ...

In this article, we demonstrate how to do this by creating a verifiable and replicable method of prompt science that aids in ...

After two strong years, 2025 was expected to mark another high-growth chapter for the MedTech industry, particularly in health technology. Instead, recent first-quarter results show a different story.

With a net margin of 6.58%, the company may face hurdles in effective cost management. Return on Equity (ROE): Chart Industries's ROE lags behind industry averages, suggesting challenges in ...

Thermo Fisher Scientific TMO is set to give its latest ... efficient use of assets and strong financial health. Debt Management: The company maintains a balanced debt approach with a debt-to ...